PegIFN-α2a for the treatment of chronic hepatitis B and C: A 10-year history

Elisabetta Degasperi, Mauro Viganò, Alessio Aghemo, Pietro Lampertico, Massimo Colombo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Chronic HBV and HCV are progressive diseases leading to cirrhosis and liver transplantation. Persistent viral eradication or suppression can positively affect the natural course of the infection, by preventing disease progression. Since its introduction more than 30 years ago, IFN-α has represented the foundation of HBV and, lately, anti-HCV treatment. Pegylation of the IFN-α molecule (PegIFN-α2a) has provided improvements in both efficacy and administration schedule, thus becoming part of the standard-of-care regimen for HCV and HBV therapy in the last 10 years. Currently, treatment of finite duration with PegIFN-α2a may achieve a sustained virological response off-treatment and HBsAg seroconversion. PegIFN-α2a will most likely remain the backbone of HCV treatment for the next few years, despite the availability of direct-acting antivirals that are expected to improve cure rates. However, many efforts are concentrated on developing new compounds, with the goal of administrating all oral regimens and eliminating PegIFN from anti-HCV treatment.

Original languageEnglish
Pages (from-to)459-474
Number of pages16
JournalExpert Review of Anti-Infective Therapy
Volume11
Issue number5
DOIs
Publication statusPublished - May 2013

Fingerprint

antineoplaston A10
Chronic Hepatitis B
Chronic Hepatitis C
History
Therapeutics
Standard of Care
Hepatitis B Surface Antigens
Liver Transplantation
Antiviral Agents
Disease Progression
Appointments and Schedules
Fibrosis
Infection

Keywords

  • antiviral therapy
  • boceprevir
  • HBV
  • HCV
  • nucleos(t)ide analogs
  • PegIFN-α2a
  • telaprevir

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Virology

Cite this

PegIFN-α2a for the treatment of chronic hepatitis B and C : A 10-year history. / Degasperi, Elisabetta; Viganò, Mauro; Aghemo, Alessio; Lampertico, Pietro; Colombo, Massimo.

In: Expert Review of Anti-Infective Therapy, Vol. 11, No. 5, 05.2013, p. 459-474.

Research output: Contribution to journalArticle

@article{b75e174a785340b2b0bffcda7830f13f,
title = "PegIFN-α2a for the treatment of chronic hepatitis B and C: A 10-year history",
abstract = "Chronic HBV and HCV are progressive diseases leading to cirrhosis and liver transplantation. Persistent viral eradication or suppression can positively affect the natural course of the infection, by preventing disease progression. Since its introduction more than 30 years ago, IFN-α has represented the foundation of HBV and, lately, anti-HCV treatment. Pegylation of the IFN-α molecule (PegIFN-α2a) has provided improvements in both efficacy and administration schedule, thus becoming part of the standard-of-care regimen for HCV and HBV therapy in the last 10 years. Currently, treatment of finite duration with PegIFN-α2a may achieve a sustained virological response off-treatment and HBsAg seroconversion. PegIFN-α2a will most likely remain the backbone of HCV treatment for the next few years, despite the availability of direct-acting antivirals that are expected to improve cure rates. However, many efforts are concentrated on developing new compounds, with the goal of administrating all oral regimens and eliminating PegIFN from anti-HCV treatment.",
keywords = "antiviral therapy, boceprevir, HBV, HCV, nucleos(t)ide analogs, PegIFN-α2a, telaprevir",
author = "Elisabetta Degasperi and Mauro Vigan{\`o} and Alessio Aghemo and Pietro Lampertico and Massimo Colombo",
year = "2013",
month = "5",
doi = "10.1586/eri.13.37",
language = "English",
volume = "11",
pages = "459--474",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - PegIFN-α2a for the treatment of chronic hepatitis B and C

T2 - A 10-year history

AU - Degasperi, Elisabetta

AU - Viganò, Mauro

AU - Aghemo, Alessio

AU - Lampertico, Pietro

AU - Colombo, Massimo

PY - 2013/5

Y1 - 2013/5

N2 - Chronic HBV and HCV are progressive diseases leading to cirrhosis and liver transplantation. Persistent viral eradication or suppression can positively affect the natural course of the infection, by preventing disease progression. Since its introduction more than 30 years ago, IFN-α has represented the foundation of HBV and, lately, anti-HCV treatment. Pegylation of the IFN-α molecule (PegIFN-α2a) has provided improvements in both efficacy and administration schedule, thus becoming part of the standard-of-care regimen for HCV and HBV therapy in the last 10 years. Currently, treatment of finite duration with PegIFN-α2a may achieve a sustained virological response off-treatment and HBsAg seroconversion. PegIFN-α2a will most likely remain the backbone of HCV treatment for the next few years, despite the availability of direct-acting antivirals that are expected to improve cure rates. However, many efforts are concentrated on developing new compounds, with the goal of administrating all oral regimens and eliminating PegIFN from anti-HCV treatment.

AB - Chronic HBV and HCV are progressive diseases leading to cirrhosis and liver transplantation. Persistent viral eradication or suppression can positively affect the natural course of the infection, by preventing disease progression. Since its introduction more than 30 years ago, IFN-α has represented the foundation of HBV and, lately, anti-HCV treatment. Pegylation of the IFN-α molecule (PegIFN-α2a) has provided improvements in both efficacy and administration schedule, thus becoming part of the standard-of-care regimen for HCV and HBV therapy in the last 10 years. Currently, treatment of finite duration with PegIFN-α2a may achieve a sustained virological response off-treatment and HBsAg seroconversion. PegIFN-α2a will most likely remain the backbone of HCV treatment for the next few years, despite the availability of direct-acting antivirals that are expected to improve cure rates. However, many efforts are concentrated on developing new compounds, with the goal of administrating all oral regimens and eliminating PegIFN from anti-HCV treatment.

KW - antiviral therapy

KW - boceprevir

KW - HBV

KW - HCV

KW - nucleos(t)ide analogs

KW - PegIFN-α2a

KW - telaprevir

UR - http://www.scopus.com/inward/record.url?scp=84877014011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877014011&partnerID=8YFLogxK

U2 - 10.1586/eri.13.37

DO - 10.1586/eri.13.37

M3 - Article

C2 - 23627852

AN - SCOPUS:84877014011

VL - 11

SP - 459

EP - 474

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 5

ER -